Confronting cancer with clinical trials
-
myMDAnderson
Log in to our secure, personalized website to manage your care.
-
Request an Appointment
Request an Appointment
If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment Information - Donate Today
MENU
Brain Tumor Clinical Trials
Below is a list of brain tumor clinical trials run by the Neuro-Oncology and Neurosurgery departments at MD Anderson. We have clinical trials for many brain tumors, including glioblastoma, meningioma, ependymoma and brain metastases.
Trial availability may change without notice. Individual trial spots may open or close without notice. Click on the study link for detailed information about each clinical trial.
Last updated 5/23/2017
Glioblastoma - newly diagnosed
Study: 2015-0869
Phase IIb/III
Treatment agent: ABT-414
Newly diagnosed glioblastoma with epidermal growth factor receptor (EGFR) amplification
NIH link: NCT No: NCT02573324
Glioblastoma - recurrent
Study: 2014-0820
Phase II
Treatment agent: Pembrolizumab
Recurrent glioblastoma
This trial is only available at MD Anderson
NIH link: NCT No: NCT02337686
Study: 2014-0899
Phase I/II
Treatment agent: CMV-stimulated adoptive T cells
Recurrent glioblastoma
This trial is only available at MD Anderson
NIH link: NCT No: NCT02661282
Study: 2015-0864
Phase II
Treatment agent: Crenolanib
Recurrent glioblastoma with PDGFRA gene amplification
This trial is only available at MD Anderson
NIH link: NCT No: NCT02626364
Study: 2016-0252
Phase II
Treatment agent: VAL-083
Unmethylated MGMT recurrent glioblastoma
This trial is only available at MD Anderson
NIH link: NCT No: NCT02717962
Study: 2016-0433
Phase II
Treatment agent: Adenovirus (DNX-2401) with Pembrolizumab
Recurrent glioblastoma or gliosarcoma
NIH link: NCT No: NCT02798406
Study: 2016-0614
Pilot trial
Treatment agent: Pembrolizumab
Recurrent glioblastoma
NIH link: NCT No: NCT02852655
Anaplastic glioma (grade III) – recurrent
Study: 2016-0330
Phase III
Treatment agent: Lomustine and Eflornithine
First recurrence of grade III anaplastic astrocytoma
NIH link: NCT No: NCT02796261
Meningioma
Study: ALLIANCE A071401
Phase II
Treatment agent: GSK2256098
Progressive meningiomas with SMO/SKT/NF2 mutations
NIH link: NCT No: NCT02523014
Ependymoma
Study: CERN09-02
Phase II
Treatment agent: Bevacizumab
Recurent ependymoma
NIH link: NCT No: NCT01295944
Brain metastases and/or leptomeningeal disease
Study: 2016-0192
Phase II
Treatment agent: Tesevatinib
Non-small cell lung cancer with EGFR activating mutation and brain metastases or leptomeningeal metastases
NIH link: NCT No: NCT02616393
Study: ALLIANCEA221208
Phase II
Treatment agent: Bevacizumab
Radionecrosis after radiosurgery for brain metastases
NIH link: NCT No: NCT02490878
Non-therapeutic and/or symptom control
Study: 2012-0441
Prospective assessment of correlative biomarkers in CNS patients (the PROACTIVE Program), a biomarker-driven program for clinical trial development for newly diagnosed and recurrent CNS patients
Study: 2013-0348
Ivy Foundation early phase clinical trials consortium (Ivy CTC) virtual tissue bank for malignant glioma patients
All Clinical Trials
MD Anderson patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.
Several other departments, including Radiation Oncology and Investigational Cancer Therapeutics, also offer clinical trials that may be open to brain tumor patients.